Disclosed is a liposome for use in the manufacture of a pharmaceutical composition for the treatment or prevention of conditions including endometriosis, ischemia-reperfusion injury, myocardial infarction, and restenosis. A liposome having a lipid component and an encapsulated therapeutic agent, wherein the mass ratio of the therapeutic agent to the lipid is about 1: 5 to 1: 8, and the lipid component comprises DSPC, DSPG, and cholesterol in a molar ratio of about Liposomes containing 3: 1: 2 and having a liposome compression ratio of less than 0.70 ml / g. Use of the liposome, wherein the therapeutic agent is a bisphosphonate. A liposome formulation containing the therapeutic agent and a method for producing the formulation. [Selection diagram] FIG.【課題】実質的に子宮内膜症、虚血再灌流障害、心筋梗塞、及び再狭窄を含む症状の治療又は予防に用いる医薬組成物の製造に用いるリポソームの提供。【解決手段】脂質成分と封入された治療剤を有するリポソームであって、治療剤対脂質の質量比が約１：５～１：８であり、脂質成分がＤＳＰＣ、ＤＳＰＧ、コレステロールをモル比約３：１：２で含有し、リポソームの圧縮率が０．７０ｍｌ／ｇ未満であるリポソーム。治療剤がビスホスホネートである、前記リポソームの使用。前記治療剤を含むリポソーム処方剤と、この処方剤の製造方法。【選択図】図４
